Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I'm in HAUP now. Went from 4 to 6 the last four years.
That's me 5000 @3.63.
I not exactly sure, but there is a good chance (I feel) that some new stock is being sold into the float. Probably the stock that shows up under my Scottrade account as that was filed in early October.
The financing give a support level to the stock. I'll bet the stock won't drop below .25. Anything below .25 would probably be a buy.
If they COULD get approved for NASDAQ (with RS), you could see the price triple. The good news is: the management said they intended to do this, that is a listing, NASDAQ would be best, AMEX would be so so.
Yes, I play the market. GTEC was looking good, but now I'm trying to tell if it's turning into a diluter.
It's not a waste of time. One of the biggest issues with the OTCBB is DILUTION and death financing.
Check out NMKT.OB for more info. Sales, earnings and a lot of people were thinking this would go to a dollar.
About "sell stock". Check you Scottrade research under insider transaction, and you will see what I mean. No bash, go look!
And I told you they sent me that e-mail yesterday, and stand by it. If it's crap, then that's what thesubway.com is sending out about GTEC.
Things change almost daily in the market, because of this, now I MAY buy some under .20, but the price will probably hang around .25 - .30.
I'm out with a 50% gain.
If you have Scottrade as your broker you should look under "quotes and research" put in GTEC. It states that a firm filed to sell 852,640.00 shares on October 9, 2007. "Planned sale"
I think this is a good thing to know.
I feel you people are too bullish.
I wouldn't pay much more then the PP price (average .27) if I was going to reinter this stock, until I see more news. I don't think I will reenter because the disclaimer from subway put up a lot of red flags to me. But if good news comes out I may change.
I cannot recommend to somebody what to do because you have to take verified information and decide for yourself.
To say that I posted old information to try to cause trouble here is just nonsense. To try to manipulate the stock like this is criminal.
They alway put thoses disclaimer at the end because legally they have to, and many times their getting ready to sell stock.
At least the OTCBB is giving GTEC a 5 PE.
One more time: this is the exact email that was sent to me, and I ASSUME hundreds of other. I posted it here because it pertains to GTEC:
GTEC New Agreement To Boost New Drug Discoveries! - 2290:112376
news@thesubway.com
Sent: Wed 11/21/07 10:37 AM
GTEC New Agreement To Boost New Drug Discoveries!
Genesis Pharmaceuticals Announces Cooperation Agreement with The Institute of Microbiology, Chinese Academy of Sciences
Genesis Pharmaceuticals Enterprises, Inc. (OTCBB:GTEC) ("Genesis" or the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that it signed a cooperation agreement with The Institute of Microbiology, Chinese Academy of Sciences (IMCAS), a research institution in China that performs a wide spectrum of basic and applied research in the field of microbiology.
According to the cooperation agreement, Genesis and IMCAS will build a "Genesis Pharmaceuticals Industrialization Model" to do joint research with the goal of commercializing pharmaceutical discoveries. This Industrialization Model is IMCAS' first cooperative arrangement with a pharmaceuticals manufacturing company.
Genesis will fund the Industrialization Model's daily operations and research and development activities. Once new drugs have completed a first stage of experiments in the Industrialization Model, they will be delivered to Genesis's factory for further testing to determine the viability of commercial wide-scale production. Genesis' research and development staff will work with researchers from IMCAS to resolve issues that arise during the process of designing the manufacturing process for new drugs. Genesis will have the first right to purchase patents for any products developed by the Industrialization Model and IMCAS.
"We are very pleased that IMCAS chose Genesis to be its partner in the commercialization of new drug discoveries," said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises, Inc. "Because IMCAS is the national leading research institution in the field of microbiology, we believe collaboration will bring valuable research and develop expertise to Genesis and strengthen our own R&D force. This will extend our company's use of cutting edge technologies as well as solidify our leading position in the Chinese pharmaceutical market."
About IMCAS
The Institute of Microbiology, Chinese Academy of Sciences (IMCAS) was founded on December 3, 1958. It is a national comprehensive research institution that performs a wide spectrum of basic and applied research in the field of microbiology. IMCAS hosts 300 faculty and staff, including 5 CAS academicians. Currently, it has three key laboratories: State Key Laboratory of Microbial Resources, State Key Laboratory of Plant Genomics, and CAS Key Laboratory of Systematic Mycology and Lichenology as well as nine research centers which carry out studies on microbial resources, microbial genomics, agricultural biotechnology, bio-energy and industrial biotechnology, environmental biotechnology, extremophiles, microbial metabolic engineering, molecular virology, and molecular immunology, As the national leading research and development organization in China, IMCAS successfully developed SARS vaccine.
As the national leading research institution in the field of microbiology, the IMCAS is committed to the advancement of science and technology. During the last 40 years, it has attained a number of developmental achievements in molecular evolution, pathogenicity, and cross-species propagation, as well as antiviral fields which can be the initial force for industrialization process.
About Genesis Pharmaceuticals Enterprises
Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing tablets, capsules, and granules for both western and Chinese herbal-based medical drugs. The Company maintains a representative office in the U.S. For more information, refer to http://www.Genesis-China.net
Safe Harbor Statement
Certain statements set forth in this press release constitute "forward-looking statements." Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
This news release was distributed by PrimeNewswire, www.primenewswire.com
SOURCE: Genesis Pharmaceuticals Enterprises, Inc.
--------------------------------------------------------------------------------
Remove from List
Please allow 2-3 days to be removed.
All material herein was prepared by CRG Partners, Inc. (CRGP) based upon information believed to be reliable. The information contained herein is not guaranteed by CRGP to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRGP is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRGP has been compensated by third party shareholders with shares or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRGP has been compensated one hundred thousand restricted LTUS shares for GTEC. For promotional work prior to the licensing of TheSUBWAY to CRGP, CRG was compensated five million four hundred thousand restricted shares of Genesis Technology Group Inc. (GTEC). CRG also received six hundred thousand common shares of GTEC, and additional compensation of ten thousand dollars. CRG also purchased three hundred ten thousand GTEC shares in the open market. CRG has sold GTEC shares, and intends to continue to sell its shares and to purchase and sell additional shares of GTEC. An officer of CRG is the sole owner of a limited liability company (the LLC) that is a member of and owns 25 percent of Genesis Equity Partners (GEP) a limited liability company of which GTEC is a member and owns a fifty one percent interest. GEP is a general partner in a partnership agreement with Lotus Pharmaceuticals, Inc. (OTCBB: LTUS) hereafter Lotus, a publicly traded company, whereby GEP for a period of 18 months is a non exclusive external consultant in connection with financial and related matters. Under that partnership agreement the members of GEP received Lotus stock; the LLC owned by an officer of CRG received 3,302,400 shares of Lotus stock. The LLC intends to sell its shares of Lotus. GEP also receives a fee of $10,000 per month from Lotus. CRGP intends to sell its shares. CRGP has sold approximately zero LTUS or GTEC shares to date. CRGP may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRGP and its web site operates under a license from Capital Research Group, Inc., TheSUBWAY.com Inc. and One Source Solutions Inc. (Licensors) and CRGP is not the agent of any of the Licensors and CRGP is solely responsible for all statements made herein. CRGP's Licensors, affiliates, officers, directors and employees own shares and intend to buy and sell additional shares of the company mentioned herein and may profit in the event those shares rise in value. CRGP will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
ABOUT US | WHAT'S NEW | CONTACT US | LINK TO US | PRIVACY
Your dreaming pal. This is the exact email sent me and hundreds of others from www.thesubway.com.
How do you get it's erroneous??? I think this takes the cake that you should think that it's erroneous. I don't post false information as I am accountable for it.
So kick me off the board because I posted something about GTEC that you didn't like.
Check these China drug related stocks. Great earnings but around a 5 PE.CHME did a little slip up at earning and 30% price was lost.
http://www.knobias.com/individual/public/quote.htm?ticker=CHME
http://www.knobias.com/individual/public/quote.htm?ticker=CPHI
No, not when I saw the earning and them using subway.com.
I was thinking they were not your normal OTCBB diluter, but now I think they may be.
The shares now I feel are overvalued by about .05.
Make sure you get out before the dump.
It's like those P&D flyers you get email, and snail mail.
Here is the email I got TODAY:
GTEC New Agreement To Boost New Drug Discoveries!
Genesis Pharmaceuticals Announces Cooperation Agreement with The Institute of Microbiology, Chinese Academy of Sciences
Genesis Pharmaceuticals Enterprises, Inc. (OTCBB:GTEC) ("Genesis" or the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that it signed a cooperation agreement with The Institute of Microbiology, Chinese Academy of Sciences (IMCAS), a research institution in China that performs a wide spectrum of basic and applied research in the field of microbiology.
According to the cooperation agreement, Genesis and IMCAS will build a "Genesis Pharmaceuticals Industrialization Model" to do joint research with the goal of commercializing pharmaceutical discoveries. This Industrialization Model is IMCAS' first cooperative arrangement with a pharmaceuticals manufacturing company.
Genesis will fund the Industrialization Model's daily operations and research and development activities. Once new drugs have completed a first stage of experiments in the Industrialization Model, they will be delivered to Genesis's factory for further testing to determine the viability of commercial wide-scale production. Genesis' research and development staff will work with researchers from IMCAS to resolve issues that arise during the process of designing the manufacturing process for new drugs. Genesis will have the first right to purchase patents for any products developed by the Industrialization Model and IMCAS.
"We are very pleased that IMCAS chose Genesis to be its partner in the commercialization of new drug discoveries," said Mr. Cao Wubo, Chairman and CEO of Genesis Pharmaceuticals Enterprises, Inc. "Because IMCAS is the national leading research institution in the field of microbiology, we believe collaboration will bring valuable research and develop expertise to Genesis and strengthen our own R&D force. This will extend our company's use of cutting edge technologies as well as solidify our leading position in the Chinese pharmaceutical market."
About IMCAS
The Institute of Microbiology, Chinese Academy of Sciences (IMCAS) was founded on December 3, 1958. It is a national comprehensive research institution that performs a wide spectrum of basic and applied research in the field of microbiology. IMCAS hosts 300 faculty and staff, including 5 CAS academicians. Currently, it has three key laboratories: State Key Laboratory of Microbial Resources, State Key Laboratory of Plant Genomics, and CAS Key Laboratory of Systematic Mycology and Lichenology as well as nine research centers which carry out studies on microbial resources, microbial genomics, agricultural biotechnology, bio-energy and industrial biotechnology, environmental biotechnology, extremophiles, microbial metabolic engineering, molecular virology, and molecular immunology, As the national leading research and development organization in China, IMCAS successfully developed SARS vaccine.
As the national leading research institution in the field of microbiology, the IMCAS is committed to the advancement of science and technology. During the last 40 years, it has attained a number of developmental achievements in molecular evolution, pathogenicity, and cross-species propagation, as well as antiviral fields which can be the initial force for industrialization process.
About Genesis Pharmaceuticals Enterprises
Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing tablets, capsules, and granules for both western and Chinese herbal-based medical drugs. The Company maintains a representative office in the U.S. For more information, refer to http://www.Genesis-China.net
Safe Harbor Statement
Certain statements set forth in this press release constitute "forward-looking statements." Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to introduce, manufacture and distribute new drugs. Actual results may differ materially from predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
This news release was distributed by PrimeNewswire, www.primenewswire.com
SOURCE: Genesis Pharmaceuticals Enterprises, Inc.
--------------------------------------------------------------------------------
Remove from List
Please allow 2-3 days to be removed.
All material herein was prepared by CRG Partners, Inc. (CRGP) based upon information believed to be reliable. The information contained herein is not guaranteed by CRGP to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. CRGP is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.thesubway.com or mentioned herein. CRGP has been compensated by third party shareholders with shares or with cash from the company on behalf of one or more of the companies mentioned in this opinion. CRGP has been compensated one hundred thousand restricted LTUS shares for GTEC. For promotional work prior to the licensing of TheSUBWAY to CRGP, CRG was compensated five million four hundred thousand restricted shares of Genesis Technology Group Inc. (GTEC). CRG also received six hundred thousand common shares of GTEC, and additional compensation of ten thousand dollars. CRG also purchased three hundred ten thousand GTEC shares in the open market. CRG has sold GTEC shares, and intends to continue to sell its shares and to purchase and sell additional shares of GTEC. An officer of CRG is the sole owner of a limited liability company (the LLC) that is a member of and owns 25 percent of Genesis Equity Partners (GEP) a limited liability company of which GTEC is a member and owns a fifty one percent interest. GEP is a general partner in a partnership agreement with Lotus Pharmaceuticals, Inc. (OTCBB: LTUS) hereafter Lotus, a publicly traded company, whereby GEP for a period of 18 months is a non exclusive external consultant in connection with financial and related matters. Under that partnership agreement the members of GEP received Lotus stock; the LLC owned by an officer of CRG received 3,302,400 shares of Lotus stock. The LLC intends to sell its shares of Lotus. GEP also receives a fee of $10,000 per month from Lotus. CRGP intends to sell its shares. CRGP has sold approximately zero LTUS or GTEC shares to date. CRGP may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRGP and its web site operates under a license from Capital Research Group, Inc., TheSUBWAY.com Inc. and One Source Solutions Inc. (Licensors) and CRGP is not the agent of any of the Licensors and CRGP is solely responsible for all statements made herein. CRGP's Licensors, affiliates, officers, directors and employees own shares and intend to buy and sell additional shares of the company mentioned herein and may profit in the event those shares rise in value. CRGP will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
ABOUT US | WHAT'S NEW | CONTACT US | LINK TO US | PRIVACY POLICY | TERMS OF USE | DISCLAIMER
The best way they can get meaningful attention is listing on an exchange. Subway is considered a P&D by many.
I just got it in my email. Here is the date: news@thesubway.com
Sent: Wed 11/21/07 10:37 AM
I'm not trying to bash, just posting what I've found.
MORE stock is coming. Subway is pumping GTEC and getting paid shares for it:
"The SUBWAY to CRGP, CRG was compensated five million four hundred thousand restricted shares of Genesis Technology Group Inc. (GTEC). CRG also received six hundred thousand common shares of GTEC, and additional compensation of ten thousand dollars. CRG also purchased three hundred ten thousand GTEC shares in the open market. CRG has sold GTEC shares, and intends to continue to sell its shares and to purchase and sell additional shares of GTEC. An officer of CRG is the sole owner of a limited liability company (the LLC) that is a member of and owns 25 percent of Genesis Equity Partners (GEP) a limited liability company of which GTEC is a member and owns a fifty one percent interest. GEP is a general partner in a partnership agreement with Lotus Pharmaceuticals, Inc. (OTCBB: LTUS) hereafter Lotus, a publicly traded company, whereby GEP for a period of 18 months is a non exclusive external consultant in connection with financial and related matters. Under that partnership agreement the members of GEP received Lotus stock; the LLC owned by an officer of CRG received 3,302,400 shares of Lotus stock. The LLC intends to sell its shares of Lotus. GEP also receives a fee of $10,000 per month from Lotus. CRGP intends to sell its shares. CRGP has sold approximately zero LTUS or GTEC shares to date. CRGP may sell its shares for less than the target price given in this opinion. In addition to any compensation mentioned above, additional compensation can be equal to ten percent of any newly issued or registered securities of the profiled companies. CRGP and its web site operates under a license from Capital Research Group, Inc., TheSUBWAY.com Inc. and One Source Solutions Inc. (Licensors) and CRGP is not the agent of any of the Licensors and CRGP is solely responsible for all statements made herein. CRGP's Licensors, affiliates, officers, directors and employees own shares and intend to buy and sell additional shares of the company mentioned herein and may profit in the event those shares rise in value. CRGP will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market."
It's says "public reply".
That means anybody who has a account here can reply.
Don't get mad because things didn't work out like you were thinking.....try to learn.
No it's not at a new high and tax selling is starting already.
Support is around .26 which is probably where it will be when the tax selling starts in December. There are a lot of buys .35++++++++.
Without news, it's probably not going anywhere, soon.
Settle down, GTEC should be ok once they get off the OTCBB.
Just putting a little reality back into the board.
Is it wise to hear the pros without the cons???....I'll let you answer that.
Or is it being negative because you point a few observations.
Think about this: a battery on your car has a positive and negative terminal and cannot work without each.
Could see a long squeeze cause tax selling season has started.
NITE knows there is not a lot of volume and he can short the retail.
I like this:
"Over the next several quarters we plan to take the steps required to move Genesis Pharmaceuticals to a major stock market in the U.S. so as to attain greater visibility with investors and the media and enhance the marketability of our stock."
It's valuation, OTCBB is a junk exchange (PE 5 rule), most but not all is junk.
There are are trading opportunities
God forbid, I'm not trying to be hateful, but realistic.
A bull and a bear make a market. Not a just a bull (or bear).
The financing gives GTEC support around an average of .27. GTEC is a lot better off then they were. Up 200% in a few months.
I feel you guys are too bullish here. GTEC will probably go higher but it won't be as fast as most people are expecting.
You're 100% right, you don't invest in pinks, you trade them.
Most OTCBB aren't investable either.
Here again I ask: are you a novice? because you cannot compare a pink sheet "stock" with a OTCBB stock, that is DPBM.
Being pessimistic (realistic) can save you a lot of money.
I sold mine for around .40 for a 60% gain. I not looking to buy again as I feel GTEC is fully valued around .25, unless more news comes out.
Thank you, I'm just trying to help. A lot of novice-starter traders here.
No, need to give it a couple of days.
NITE & company may try to sucker in a lot of newbies.
The quarterly report is good but FOR A OTCBB STOCK, GTEC is fully valued around .25 - .30 cents. If it was on the NASD or AMEX it would trade at a higher PE
CMED is NASDAQ, not the OTCBB, it's foolish to compare a listed and OTCBB stock, but you'll find out in a day or three.
You guys are dreaming or novices or what?????????????.
The easy money was already made in GTEC. If it ever does make to a dollar, it will be a long hard grind.
Now, IF GTEC applies and is excepted for a exchange listing, thing COULD change.
WHERE you are trading makes all the difference in the world.
So are about 10 other China stocks. Do some study here. Market still won't give more then a 5 PE. http://investorshub.advfn.com/boards/board.asp?board_id=7653
Just watch, when all the dust settles GTEC won't trade at much more then a 5 PE.
This is part of the reason why China stocks only trade at around a 5 PE: http://investorshub.advfn.com/boards/read_msg.asp?message_id=15549611
The thing you people fail to realize is: until this "company" gets close to around 20M in revs and making money, it won't be considered much of anything by anybody, except traders gambling in speculation.
The risk here is ENORMOUS.
I just hope you longs don't lose everything. A lot of money has been lost in stocks especially the OTCBB.
The price action speaks volumes. There may be a short lived bounce here, thats about all.
Support is at .005 and with the next round of dilution or tax selling, that will be tested. Just watch.
RS is in the cards.
Some of the longs are in denial of what is happening here.
A little expensive here. Cheap around .25.